drug:orforglipron
Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
drug:orforglipron
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
category:news
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
drug:eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
company:eli-lilly
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
drug:retatrutide
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
company:eli-lilly
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
drug:mounjaro
Eli Lilly's Mounjaro launches in India
category:news
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
politics
Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
category:news
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
category:watercooler
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:howto
What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.